Healthcare entity
Every one of those 1 sits in a single category, regulation. KLTO-202 is most often covered alongside Australian Patent No. 2023252508, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. KLTO-202 appears in 1 tracked Healthcare story from July 11, 2026.
Last mentioned: Jul 11, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. KLTO-202 is most often covered alongside Australian Patent No. 2023252508, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. KLTO-202 appears in 1 tracked Healthcare story from July 11, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering KLTO-202. Shared-story counts are live from our verified record — not editorial picks.
A newly granted Australian patent protects a Klotho-based gene therapy for ALS and other neuromuscular diseases. The technology, called KLTO-202, aims to restore a critical protein, offering hope for patients with limited treatment options.
Source: The Manila Times · Financial Post
KLTO-202 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
